Journey Medical Co. (NASDAQ:DERM) Director Lindsay A. Md Rosenwald Acquires 10,000 Shares of Stock

Journey Medical Co. (NASDAQ:DERM) Director Lindsay A. Md Rosenwald acquired 10,000 shares of Journey Medical stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the purchase, the director now directly owns 144,245 shares of the company’s stock, valued at $438,504.80. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Journey Medical Stock Performance

Journey Medical stock opened at $3.89 on Thursday. Journey Medical Co. has a 12 month low of $1.02 and a 12 month high of $8.11.

Analysts Set New Price Targets

Separately, Alliance Global Partners started coverage on Journey Medical in a research report on Friday, February 16th. They issued a “buy” rating and a $8.50 target price for the company.

Hedge Funds Weigh In On Journey Medical

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Journey Medical by 78.1% during the fourth quarter. Vanguard Group Inc. now owns 129,448 shares of the company’s stock worth $746,000 after purchasing an additional 56,781 shares during the period. Virtu Financial LLC acquired a new stake in Journey Medical in the fourth quarter valued at approximately $153,000. Northern Trust Corp acquired a new stake in Journey Medical in the fourth quarter valued at approximately $96,000. Finally, Citadel Advisors LLC purchased a new position in shares of Journey Medical during the fourth quarter valued at approximately $65,000. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.